private:xcovery
|
647976
|
Dec 3rd, 2020 12:00AM
|
Xcovery
|
694
|
20.00
|
Open
|
Biotechnology
|
Dec 3rd, 2020 03:30PM
|
Dec 3rd, 2020 03:30PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Dec 2nd, 2020 12:00AM
|
Xcovery
|
694
|
20.00
|
Open
|
Biotechnology
|
Dec 2nd, 2020 05:17PM
|
Dec 2nd, 2020 05:17PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Dec 1st, 2020 12:00AM
|
Xcovery
|
695
|
20.00
|
Open
|
Biotechnology
|
Dec 1st, 2020 03:54PM
|
Dec 1st, 2020 03:54PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Nov 30th, 2020 12:00AM
|
Xcovery
|
694
|
20.00
|
Open
|
Biotechnology
|
Nov 29th, 2020 09:49PM
|
Nov 30th, 2020 06:48PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Nov 28th, 2020 12:00AM
|
Xcovery
|
694
|
20.00
|
Open
|
Biotechnology
|
Nov 28th, 2020 05:22PM
|
Nov 28th, 2020 05:22PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Nov 27th, 2020 12:00AM
|
Xcovery
|
694
|
19.00
|
Open
|
Biotechnology
|
Nov 27th, 2020 01:49PM
|
Nov 27th, 2020 01:49PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Nov 26th, 2020 12:00AM
|
Xcovery
|
694
|
19.00
|
Open
|
Biotechnology
|
Nov 25th, 2020 08:58PM
|
Nov 25th, 2020 08:58PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Nov 24th, 2020 12:00AM
|
Xcovery
|
694
|
19.00
|
Open
|
Biotechnology
|
Nov 24th, 2020 04:32PM
|
Nov 24th, 2020 04:32PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Nov 23rd, 2020 12:00AM
|
Xcovery
|
694
|
19.00
|
Open
|
Biotechnology
|
Nov 23rd, 2020 06:21PM
|
Nov 23rd, 2020 06:21PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|
private:xcovery
|
647976
|
Nov 22nd, 2020 12:00AM
|
Xcovery
|
693
|
19.00
|
Open
|
Biotechnology
|
Nov 21st, 2020 07:06PM
|
Nov 22nd, 2020 05:17PM
|
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We are currently enrolling patients in our phase 2 and phase 3 clinical studies. Xcovery.com
|
Open
|
Oncology, ALK positive lung cancer, lung cancer, clinical trials , ALK+ NSCLC, kinase inhibitors, oncology research, bio-pharmaceutics, pharmaceutics, cancer, ALK inhibitor, ensartinib , cancer research, pharma , bio-pharma, clinical studies, research , investigational agents , cancer therapy , hematology, clinical research , cancer research
|
Open
|
11780 US Hwy 1, Suite 202
|
Palm Beach Gardens
|
Florida
|
US
|
33408
|
|
Xcovery
|
Health Care
|
Health Care Equipment & Services
|